Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The purpose of this research is to compare progression free survival between two available systemic therapies - immunotherapy and tyrosine kinase inhibitors - after Therasphere® (yttrium-90) treatment in adult patients with advanced hepatocellular carcinoma. The immunotherapy consists of a standard-of-care treatment with Atezolizumab and Bevacizumab. Treatment with tyrosine kinase inhibitors consists of standard-of-care Lenvatinib or Cabozantinib.
Epistemonikos ID: ecf1d7de3168acd08f4ea02235306275eb33fbd5
First added on: May 14, 2024